Follistatin-344 Research: The Endogenous Antagonist of Myostatin and Activin

What is follistatin-344?

What is follistatin-344? Follistatin is a single-chain, cysteine-rich secreted glycoprotein that binds members of the TGF-β superfamily — activins first and foremost, and myostatin — and prevents them from reaching their receptors. The 344 in the name is a length: the human FST gene produces alternatively spliced transcripts, and the longer one encodes a 344-amino-acid precursor. UniProt (P19883) records that precursor with a 29-residue signal peptide and a mature chain of residues 30–344, so what is actually secreted from the FST344 transcript is the 315-residue isoform conventionally written FS-315.

That distinction matters when reading a label. “Follistatin-344” names a transcript and a precursor, not a 344-residue circulating protein. The designation became widely used because it names the coding sequence carried by the gene-therapy vector AAV1.CMV.FS344 — the construct in the human trials described below. Molecular and nomenclature description only; nothing here concerns an effect in a reader.

Discovery and origin in the literature

Follistatin was not discovered in muscle biology at all. In 1987 two groups working on gonadal fluid isolated a protein that suppressed pituitary follicle-stimulating hormone release: Ueno, Ling, Ying, Esch, Shimasaki and Guillemin (PNAS, PMID 3120188) characterised it as a single-chain monomeric protein of roughly 35 kDa, and Esch and colleagues (Mol Endocrinol, PMID 3153465) published its structural characterisation in the same year. The name is descriptive of that first observed activity — follicle-stimulating-hormone statin.

Shimasaki et al. (1988, PNAS, PMID 3380788) then reported the primary structure of the human follistatin precursor and its genomic organisation, which is where the alternative splicing and the two precursor lengths enter the record. The mechanism turned out to be indirect: follistatin suppresses FSH by binding activin, and activin is what drives FSH release.

The muscle connection arrived a decade later, once myostatin had been identified. Lee & McPherron (2001, PNAS, PMID 11459935) examined myostatin regulation in vivo, including transgenic follistatin expression, and Amthor et al. (2004, Dev Biol, PMID 15136138) established the direct interaction experimentally: yeast and mammalian two-hybrid work showing follistatin and myostatin bind one another, an affinity of 5.84 × 10⁻¹⁰ M, and the requirement for the entire follistatin protein rather than any single module. In the same study, follistatin blocked myostatin-mediated suppression of Pax-3 and MyoD expression in chick limb bud and rescued muscle differentiation in micromass culture in a concentration-dependent way.

Reference data

Sequence architecture is taken from the UniProt human follistatin record (P19883); the mass below is calculated from that sequence for the unglycosylated polypeptide. Follistatin is glycosylated in vivo, so an observed mass on a real preparation will be higher and heterogeneous. No CAS number is listed for the recombinant protein, so that field is omitted.

Molecule and analytical facts only. No reconstitution volume, concentration, route or handling instruction is given or implied.

Mechanisms researchers have examined

The follistatin mechanism is ligand sequestration, and the interesting questions are all about selectivity:

• Direct ligand binding, not receptor blockade — follistatin wraps around its target ligand and occludes the surfaces that engage type I and type II receptors. Amthor et al. (2004) demonstrated the myostatin interaction directly and reported that partial follistatin modules did not reproduce it.
• Activin first, myostatin second — historically and biochemically. The activin interaction is the one follistatin was named for (Ueno et al. 1987), and it remains the higher-profile arm of its biology. Any myostatin-directed use is acting on a protein that is simultaneously an activin antagonist.
• Isoform differences are functional — Hashimoto et al. (2000, Cell Signal, PMID 11027950) reported that the activin-neutralising activity of follistatin isoforms depends on their affinity for activin, so FS-315 and FS-288 are not interchangeable. FS-288 additionally binds cell-surface heparan sulfate, which changes where it acts.
• Differential antagonism across ligands — Schneyer et al. (2008, Endocrinology, PMID 18535106) compared wild-type and mutant follistatin against activin, myostatin and GDF-11 and reported differential antagonism, which is the direct experimental basis for saying follistatin is not a selective myostatin inhibitor.
• Why the trials used the gene rather than the protein — follistatin is a large glycoprotein with rapid clearance, so the human work delivered its coding sequence by AAV rather than administering purified protein. Rodino-Klapac et al. (2009, Muscle Nerve, PMID 19208403) review the reasoning across myostatin-inhibition strategies.

Research findings by area

Preclinical gene delivery

Haidet et al. (2008, PNAS, PMID 18334646) reported long-term enhancement of skeletal muscle mass and strength in animals after single-gene administration of myostatin inhibitors, follistatin among them — the study that established the AAV-follistatin approach and led directly to the human programme. Reported as measured: these were animal experiments with durable transgene expression, not administration of a protein.

The human trials

Mendell et al. (2015, Mol Ther, PMID 25322757) conducted a phase 1/2a trial in Becker muscular dystrophy, delivering AAV1.CMV.FS344 by direct bilateral intramuscular quadriceps injection to six participants across two dose cohorts. The stated rationale for choosing the alternatively spliced FS344 sequence was to avoid potential binding to off-target sites. Six-minute-walk distance was the primary outcome: four of six participants improved (58, 125, 108 and 29 metres), two showed no change, and no adverse effects were encountered. Histological changes reported included reduced endomysial fibrosis, reduced central nucleation and more normal fibre-size distribution. Al-Zaidy et al. (2015, J Neuromuscul Dis, PMID 27858738) reported on ambulation in the same programme.

Mendell et al. (2017, Mol Ther, PMID 28279643) applied the same vector to six participants with sporadic inclusion body myositis and reported an annualised six-minute-walk change of +56.0 m/year in treated subjects against −25.8 m/year in comparison measures, alongside decreased fibrosis and improved regeneration.

The published dispute — and it is the reason to read carefully

The 2017 inclusion-body-myositis paper drew a formal published rebuttal. Greenberg (2017, Mol Ther, PMID 28927986) titled it “Unfounded Claims of Improved Functional Outcomes Attributed to Follistatin Gene Therapy in Inclusion Body Myositis” and disputed the functional-improvement conclusions drawn from that trial. The exchange is indexed in PubMed as a comment-and-reply pair and is part of the permanent record for this compound.

This page takes no side. What it reports is that follistatin has the strongest human evidence base of anything in this cluster and that the strength of that evidence has been contested in print by an independent investigator in the same journal. Both facts belong on an honest page, and a summary that cited the trials without the rebuttal would be incomplete. Note also that all of this work concerns AAV-delivered gene expression in specific neuromuscular diseases — it is not evidence about administering a follistatin protein preparation, and nothing here should be read that way.

Research models and evidence status

The models run from biochemistry and chick-embryo development through transgenic and AAV-treated animals to two small open-label human gene-therapy trials. The binding mechanism is well established; the clinical picture is small, contested and confined to gene delivery.

What is not established

No approved product contains follistatin and it holds no registered indication anywhere. There is no human trial of administered follistatin protein of any kind — the entire human record is AAV gene therapy, in twelve participants across two studies, both open-label and both from the same group. The functional conclusions of the 2017 study were formally disputed in the same journal (Greenberg 2017). Follistatin is not myostatin-selective, so effects attributed to myostatin inhibition may reflect activin or GDF-11 antagonism (Schneyer et al. 2008); its role in reproductive endocrinology through activin binding is not a peripheral detail but its founding biology. No pharmacokinetic data exist for administered follistatin protein in humans, and the isoform actually present in a given preparation determines its behaviour (Hashimoto et al. 2000). Wagner (2020) — cited on the GDF-8 page — describes the broader promise of myostatin inhibition as elusive. Nothing on this page is a benefit, an outcome or a use.

On anti-doping status, reported as fact and not as a use case: myostatin-function modifiers, including myostatin-binding proteins, are addressed under section S4 of the World Anti-Doping Agency Prohibited List, and gene-therapy approaches fall under the gene-doping provisions of section M3.

Follistatin among the myostatin-axis compounds

Sorted by mechanism rather than by marketing: GDF-8 is the ligand — myostatin itself, the endogenous brake on muscle mass. Follistatin-344 is an endogenous antagonist that neutralises that ligand (and several of its relatives) by binding it directly in the extracellular space. ACE-031 is an engineered receptor decoy — a soluble ActRIIB extracellular domain fused to an Fc region — which intercepts the same ligand family at a different point and whose clinical programme was halted on safety grounds. Follistatin and ACE-031 therefore share a broad ligand profile, and the honest lesson of the ACE-031 programme is directly relevant to reading follistatin’s.

The IGF-axis compounds in the same catalogue section act through an unrelated receptor and are not part of this pathway: IGF-1 LR3, IGF-1 DES, MGF and PEG-MGF. Mechanism context only; nothing here is a protocol, a stack or a recommendation.

How to verify this compound yourself

Follistatin is a large glycoprotein, which makes its certificate look different from a peptide certificate and makes one question unusually important:

• Which isoform is it? — FS-315 and FS-288 have different affinities and different tissue behaviour (Hashimoto et al. 2000). A certificate that says only “follistatin” has not answered the question that determines what the material does in an assay. Intact-mass measurement and the stated construct together answer it.
• Mass will not be a single number — the native protein is glycosylated, so an observed mass is a distribution above the calculated polypeptide value. A bacterially expressed non-glycosylated preparation will read close to the calculated mass instead, which is informative about the expression system rather than a defect.
• Purity by SDS-PAGE and chromatography — reported as a percentage, with host-cell protein and aggregation as separate concerns for a protein of this size.
• Bioassay, where reported — the functional check for follistatin is neutralisation of a defined amount of activin or myostatin in a reporter system. That is also the reason recombinant GDF-8 exists as a reagent.
• Endotoxin and sterility — where tested, separate quality attributes reported in EU/mg or as a sterility result, independent of purity and identity.

See how to read a COA for what each line on a certificate means, how to verify peptide purity for how the methods fit together, and the self-serve verify tool to check the exact batch on a vial in hand.

Research-grade sourcing and verification

For laboratory research use only. Follistatin-344 is not held in stock; it is listed as available to order in the sourcing catalogue, with a typical lead time of two to three weeks and a quote on request. Material supplied ships with a per-batch Certificate of Analysis reporting purity and identity confirmation at the lot level. On a protein whose name refers to a precursor length and whose isoforms behave differently, the specific construct and the measured mass are the fields worth reading first. Sourcing and identity-assurance framing only.

Frequently asked questions

Literature cited

1. Ueno N, Ling N, Ying SY, Esch F, Shimasaki S, Guillemin R. “Isolation and partial characterization of follistatin: a single-chain Mr 35,000 monomeric protein that inhibits the release of follicle-stimulating hormone.” Proc Natl Acad Sci U S A. 1987;84(23):8282–6. PMID 3120188. pubmed.ncbi.nlm.nih.gov/3120188.
2. Esch FS, Shimasaki S, Mercado M, et al. “Structural characterization of follistatin: a novel follicle-stimulating hormone release-inhibiting polypeptide from the gonad.” Mol Endocrinol. 1987;1(11):849–55. PMID 3153465. pubmed.ncbi.nlm.nih.gov/3153465.
3. Shimasaki S, Koga M, Esch F, et al. “Primary structure of the human follistatin precursor and its genomic organization.” Proc Natl Acad Sci U S A. 1988;85(12):4218–22. PMID 3380788. pubmed.ncbi.nlm.nih.gov/3380788.
4. Amthor H, Nicholas G, McKinnell I, et al. “Follistatin complexes Myostatin and antagonises Myostatin-mediated inhibition of myogenesis.” Dev Biol. 2004;270(1):19–30. PMID 15136138. pubmed.ncbi.nlm.nih.gov/15136138.
5. Lee SJ, McPherron AC. “Regulation of myostatin activity and muscle growth.” Proc Natl Acad Sci U S A. 2001;98(16):9306–11. PMID 11459935. pubmed.ncbi.nlm.nih.gov/11459935.
6. Hashimoto O, Nakamura T, Shoji H, Shimasaki S, Hayashi Y, Sugino H. “Difference between follistatin isoforms in the inhibition of activin signalling: activin neutralizing activity of follistatin isoforms is dependent on their affinity for activin.” Cell Signal. 2000;12(8):565–71. PMID 11027950. pubmed.ncbi.nlm.nih.gov/11027950.
7. Schneyer AL, Sidis Y, Gulati A, Sun JL, Keutmann H, Krasney PA. “Differential antagonism of activin, myostatin and growth and differentiation factor 11 by wild-type and mutant follistatin.” Endocrinology. 2008;149(9):4589–95. PMID 18535106. pubmed.ncbi.nlm.nih.gov/18535106.
8. Haidet AM, Rizo L, Handy C, et al. “Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors.” Proc Natl Acad Sci U S A. 2008;105(11):4318–22. PMID 18334646. pubmed.ncbi.nlm.nih.gov/18334646.
9. Rodino-Klapac LR, Haidet AM, Kota J, Handy C, Kaspar BK, Mendell JR. “Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease.” Muscle Nerve. 2009;39(3):283–96. PMID 19208403. pubmed.ncbi.nlm.nih.gov/19208403.
10. Mendell JR, Sahenk Z, Malik V, et al. “A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy.” Mol Ther. 2015;23(1):192–201. PMID 25322757. pubmed.ncbi.nlm.nih.gov/25322757.
11. Al-Zaidy SA, Sahenk Z, Rodino-Klapac LR, Kaspar B, Mendell JR. “Follistatin Gene Therapy Improves Ambulation in Becker Muscular Dystrophy.” J Neuromuscul Dis. 2015;2(3):185–192. PMID 27858738. pubmed.ncbi.nlm.nih.gov/27858738.
12. Mendell JR, Sahenk Z, Al-Zaidy S, et al. “Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes.” Mol Ther. 2017;25(4):870–879. PMID 28279643. pubmed.ncbi.nlm.nih.gov/28279643.
13. Greenberg SA. “Unfounded Claims of Improved Functional Outcomes Attributed to Follistatin Gene Therapy in Inclusion Body Myositis.” Mol Ther. 2017;25(10):2235–2237. PMID 28927986. pubmed.ncbi.nlm.nih.gov/28927986.
14. UniProt Consortium. “FST_HUMAN (P19883) — Follistatin.” uniprot.org/uniprotkb/P19883 (precursor length 344, signal peptide 1–29, chain 30–344, isoforms FS-315 and FS-288).